Quality varies significantly, and patients need to evaluate potential sources carefully
Key results: On-treatment (no interruptions): Semaglutide (Wegovy): 57% lower risk of heart attack, stroke, or death Tirzepatide: Reference comparator Including treatment gaps: Semaglutide: 29% lower risk of major adverse cardiovascular events Tirzepatide: Higher event rates in this real-world analysis Why this matters: These data suggest semaglutide may have greater cardiovascular benefit than tirzepatidea provocative finding given both are highly effective for weight loss
These changes not only affect cosmetic appearance but can also affect medication absorption, potentially reducing therapeutic efficacy
The truth is more nuanced than a simple yes or no
Consequently, FDAs conclusion that the quality system does not adequately ensure data accuracy and integrity is consistent with the fundamental principle that data integrity is a system responsibility, not a post hoc justification exercise
This typically involves administering a known dose to subjects and then taking serial blood samples over time
